- Home
- SAR vs ORIC Comparison
SAR vs ORIC Comparison
Compare SAR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAR
- ORIC
- Stock Information
- Founded
- SAR 2007
- ORIC 2014
- Country
- SAR United States
- ORIC United States
- Employees
- SAR N/A
- ORIC N/A
- Industry
- SAR Investment Managers
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- SAR Finance
- ORIC Health Care
- Exchange
- SAR Nasdaq
- ORIC Nasdaq
- Market Cap
- SAR 337.6M
- ORIC 362.9M
- IPO Year
- SAR 2007
- ORIC 2020
- Fundamental
- Price
- SAR $24.44
- ORIC $9.35
- Analyst Decision
- SAR Hold
- ORIC Strong Buy
- Analyst Count
- SAR 4
- ORIC 8
- Target Price
- SAR $24.75
- ORIC $18.83
- AVG Volume (30 Days)
- SAR 133.5K
- ORIC 2.1M
- Earning Date
- SAR 07-08-2025
- ORIC 08-11-2025
- Dividend Yield
- SAR 13.60%
- ORIC N/A
- EPS Growth
- SAR 186.33
- ORIC N/A
- EPS
- SAR 2.02
- ORIC N/A
- Revenue
- SAR $148,855,238.00
- ORIC N/A
- Revenue This Year
- SAR N/A
- ORIC N/A
- Revenue Next Year
- SAR $2.28
- ORIC N/A
- P/E Ratio
- SAR $12.13
- ORIC N/A
- Revenue Growth
- SAR 3.57
- ORIC N/A
- 52 Week Low
- SAR $21.10
- ORIC $3.90
- 52 Week High
- SAR $26.49
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- SAR 50.58
- ORIC 62.84
- Support Level
- SAR $24.05
- ORIC $8.85
- Resistance Level
- SAR $24.44
- ORIC $9.54
- Average True Range (ATR)
- SAR 0.33
- ORIC 0.74
- MACD
- SAR -0.03
- ORIC -0.07
- Stochastic Oscillator
- SAR 45.16
- ORIC 50.98
About SAR Saratoga Investment Corp New
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.